Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Gelesis, Inc.
Nektar And PureTech Merger Talks Terminated
The UK’s PureTech and US biotech Nektar have ended discussions about a potential merger which analysts did not see coming, but a deal could still happen and other companies may also make a move.
Gelesis Presents Data Showing GS200, The Device That Looks Like A Drug, Treats Obesity
Results of the LIGHT UP study, which included prediabetic and diabetic subjects, could support FDA approval of GS200.
PureTech Turns To Its Wholly Owned Pipeline Amid 2021 Loss
The US biotech saw a net loss last year despite increased sales and has decided to focus more on its wholly owned pipeline, which includes a safer formulation of a Roche pulmonary fibrosis product.
Finance Watch: SPACs Lose Their Luster As Difficulties Mount
Public Company Edition: While panelists at Biotech Showcase argued merging with a special purpose acquisition corporation is not as attractive as it used to be, firms continue to pursue this go-public alternative. Also, Hillstream launched a small IPO and Cytokinetics accessed cash from Royalty Pharma.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.